1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation

1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Martin Reck, Alexander I. Spira, Benjamin Besse, Jennifer Moriatis Wolf, Ferdinandos Skoulidis, Hossein Borghaei, Kōichi Goto, K. Park, Frank Griesinger, Enriqueta Felip, Michael Boyer, Carlos H. Barrios, Glenwood Goss, Hui Yang, Cynthia Obiozor, Suresh S. Ramalingam
Format: Artigo
Jezik:angleščina
Izdano: 2020
Online dostop:https://doi.org/10.1016/j.annonc.2020.08.1730
http://www.annalsofoncology.org/article/S0923753420417260/pdf
Oznake: Označite
Brez oznak, prvi označite!
Opis
Opisa ni na voljo.

Podobne knjige/članki